FDA clears BioSphere Embosphere microspheres:
This article was originally published in Clinica
Executive Summary
The US FDA has cleared BioSphere Medical's Embosphere Microspheres for the treatment of hypervascularised tumours and arteriovenous malformations. The microspheres are used to occlude the blood supply to the diseased tissue in a process known as embolotherapy. BioSphere has already received marketing approval for the microspheres in Canada, Australia and Europe for use in general embolisation procedures and has begun a Phase I study in the US of their use in uterine artery embolisation for the treatment of uterine fibroids.